MedTrace Logo

Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19

NCT05185284 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 217

Last updated 2022-01-11

No results posted yet for this study

Summary

This is open-labe randomized multicenter comparative Phase III study conducted in 7 medical facilities. The objective of the study is to assess the efficacy and safety of Favipiravir for parenteral administration compared with the Standard of care (SOC) in hospitalized patients with moderate COVID-19 pneumonia.

Conditions

Interventions

DRUG

Favipiravir

400 mg, lyophilizate for preparation of concentrate for solution for infusion

DRUG

Favipiravir

200 mg coated tablets

DRUG

Remdesivir

100 mg, lyophilizate for preparation of concentrate for solution for infusion

Sponsors & Collaborators

  • Solyur Pharmaceuticals Group

    collaborator UNKNOWN

  • Promomed, LLC

    lead OTHER

Principal Investigators

  • Dmitriy Pushkar, MD, Academic · Moscow State Clinical Hospital №50

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-11
Primary Completion
2021-12-30
Completion
2021-12-30

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05185284 on ClinicalTrials.gov